Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, predicts an industry wide demand for cardiac PET imaging, as a result of the Centers for Medicare & Medicaid Services (CMS) 2010 Medicare Physician Fee Schedule.

The Medicare Physician Fee Schedule outlines the payment rates for medical services paid to private physicians in the outpatient office setting. This fee schedule states that Myocardial PET perfusion imaging was increased 20% to $1,432.87 per study. The Schedule also states that Cardiovascular SPECT reimbursement for outpatient cardiology practices billing under CPT codes has been reduced by 36%. Ejection fraction and wall motion codes will now be bundled into a new global code.

Patrick Rooney, Chief Executive Officer of Positron stated, “The change in reimbursement just released by CMS is one of the most significant events for the utilization of cardiac PET in many years. The reimbursement increase for PET imaging further validates our position that the future of nuclear cardiology is PET.

One of the most important factors within the CMS ruling is that now the differential between PET and SPECT studies is greater than $1,000. This delta is substantial and confirms that the Government recognizes the benefits of cardiac PET as the best modality in the long term management of patient care and that their policies will accelerate the migration from the current standard of care in SPECT to the more efficient, better technology of cardiac PET.”

Source: Positron Corporation

You can discuss about Positron Corporation and its services in the Positron Company User Group